Vermillion this week announced Peter Roddy has joined its board, where he will chair the company' audit committee.
Roddy is currently vice president and chief financial officer of Pain Therapeutics. Previously, he was senior vice president of finance and CFO of COR Therapeutics. He also has held finance positions at MCM Laboratories, Hewlett-Packard, and Price Waterhouse & Co., now called PricewaterhouseCoopers.
James Atwood has joined Australian bioseparations firm NuSep as vice president of sales, the company said this week.
Also, Brent Weatherly has been appointed NuSep's chief technology officer.
Atwood was the CEO of proteomics software firm BioInquire, which Weatherly co-founded. NuSep this week announced it had signed a binding agreement to acquire BioInquire for up to $3 million.
Atwood and Weatherly will be based in Athens, Ga., where BioInquire was headquartered.
Martin Schneider is now chair of the advisory board of imaGenes, the company said this week.
Schneider replaces Klaus Schmidt-Menschner, who left to pursue other interests.
Schneider is head of global therapeutic research at Bayer Schering Pharma. He was previously head of global target discovery and biomarkers at Bayer. Before that, he was head of enabling technologies at Schering.
Based in Berlin, imaGenes provides genomics and proteomics services.